Here s Why Raptor Pharmaceuticals Corp #industry #pharmacy

Posted On May 16 2017 by

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …


Sick of pharmaceutical ads? Here – s why they won – t go away #dalton #pharma #services

Posted On Apr 30 2017 by

#pharmaceutical advertising # It seems like every other billboard and commercial in the U.S. is for a prescription drug. And yet consumers can t buy them without a doctor s approval. So why target consumers with these ads? Do we really have that much influence over physicians? Here s how the U.S. became one of the only countries in the world where pharmaceutical companies peddle drugs to ordinary people. Food and Drug Administration Loopholes The United States and New Zealand are the only countries in the world that allow direct-to-consumer advertising of pharmaceuticals. Most countries banned the practice in the …


Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #d #pharma

Posted On Apr 21 2017 by

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …


Why your #pharma #serialisation RFI should not be like Forrest Gump’s box of chocolates – full of surprises! #pharmaceutical #information

Posted On Apr 19 2017 by

#forrest pharma # Why your #pharma #serialisation RFI should not be like Forrest Gump’s box of chocolates – full of surprises! Published March 1, 2016 As Forrest Gump s Momma could have said, An RFI is like box of chocolates you never know what s inside. Photo courtesy of Loren Javier Now that the EU-FMD clock has started ticking, pharma companies are compelled to take action. The first step for those in the pharma industry is often to generate a RFI for their serialization/traceability system. This is completely understandable when faced with the need to create a new and unfamiliar …


Why I Won’t Cheer If Onyx Pharma Is Sold for Megabucks #pharmaceutical #industry #news

Posted On Apr 18 2017 by

#onyx pharma # Why I Won’t Cheer If Onyx Pharma Is Sold for Megabucks Sometime in the coming weeks, South San Francisco-based Onyx Pharmaceuticals (NASDAQ: ONXX ) will probably be acquired by some big drugmaker for more than $10 billion. Shareholders will count their profits. Analysts will applaud. Financial media will speculate about whether this deal will spark more acquisitions in the biotech industry. But I won’t be cheering. I’ll probably be wondering about what might have been. I’ll wonder what Onyx could have accomplished for patients, employees, the industry, and its regional economy if it had chosen to chart …


Here s Why Raptor Pharmaceuticals Corp #pharmaceutical #recruiters

Posted On Apr 12 2017 by

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …


Sick of pharmaceutical ads? Here – s why they won – t go away #pharmaceutical #companies #in #charlotte #nc

Posted On Apr 12 2017 by

#pharmaceutical advertising # It seems like every other billboard and commercial in the U.S. is for a prescription drug. And yet consumers can t buy them without a doctor s approval. So why target consumers with these ads? Do we really have that much influence over physicians? Here s how the U.S. became one of the only countries in the world where pharmaceutical companies peddle drugs to ordinary people. Food and Drug Administration Loopholes The United States and New Zealand are the only countries in the world that allow direct-to-consumer advertising of pharmaceuticals. Most countries banned the practice in the …


Why I Won’t Cheer If Onyx Pharma Is Sold for Megabucks #pharma #industry #jobs

Posted On Apr 8 2017 by

#onyx pharma # Why I Won’t Cheer If Onyx Pharma Is Sold for Megabucks Sometime in the coming weeks, South San Francisco-based Onyx Pharmaceuticals (NASDAQ: ONXX ) will probably be acquired by some big drugmaker for more than $10 billion. Shareholders will count their profits. Analysts will applaud. Financial media will speculate about whether this deal will spark more acquisitions in the biotech industry. But I won’t be cheering. I’ll probably be wondering about what might have been. I’ll wonder what Onyx could have accomplished for patients, employees, the industry, and its regional economy if it had chosen to chart …


What is a CRO, and why would you want to work for one: London Blog #akela #pharma #inc

Posted On Apr 3 2017 by

#cro pharma # The second of four posts on alternative careers, based on presentations at the Source Event 2008 A simplistic view of lab-based careers might split the options into academic research or work in the industrial sector. Either route, but particularly the latter, can encompass a broad spectrum of roles and goals. Working in industry need not mean that you’re part of a big pharma company like Glaxo or Pfizer, as Elizabeth Allen explained at this year’s Source Event . Allen designs Phase I clinical trials for a living. She works for Quintiles. a contract research organisation ( CRO …


Why I Won’t Cheer If Onyx Pharma Is Sold for Megabucks #pharma #companies

Posted On Mar 29 2017 by

#onyx pharma # Why I Won’t Cheer If Onyx Pharma Is Sold for Megabucks Sometime in the coming weeks, South San Francisco-based Onyx Pharmaceuticals (NASDAQ: ONXX ) will probably be acquired by some big drugmaker for more than $10 billion. Shareholders will count their profits. Analysts will applaud. Financial media will speculate about whether this deal will spark more acquisitions in the biotech industry. But I won’t be cheering. I’ll probably be wondering about what might have been. I’ll wonder what Onyx could have accomplished for patients, employees, the industry, and its regional economy if it had chosen to chart …